Author + information
- Alexandre M. Benjo,
- Shashi Kumar,
- Firas Kaddaha,
- Chaithanya Pamidimukala,
- Georges El Hayek,
- Cezar Benjo,
- Marcos Molina,
- Salim Kanaan,
- Eyal Herzog and
- Emad Aziz
Defibrillators are a cornerstone in prolonging life in patients with severe cardiomyopathy. In other hand defibrillator shocks are related not only with discomfort but also to worse prognosis. Anti-arrhythmics drugs (AAD) may prevent some shocks but as they have also proarrhythmic effect their net benefit is still unclear.
We searched PubMed, and Scopus databases from 1966 through August 2012. The studied outcomes were number shock incidence and total deaths. We performed fixed effect analysis when I2 up to 50% and P />at least 0.05, otherwise we used random effect analysis.
Out of 3177 evaluated articles, eight met the search criteria and were included in this analysis. 1520 patients were evaluated, 936 in the AAD and 584 in the control groups. Amiodarone, Sotalol and Azimilide were studied. As shown in Figure 1A, the chance of being shock free significantly increased in 57%, p < 0.0001. This benefit was not associated with increase in death (Figure 1B).
This meta-analysis supports that the use of Class III anti-arrhythmics is safe in patients with defibrillator and may benefit patients decreasing the number of shocks.
Poster Sessions, Expo North
Sunday, March 10, 2013, 9:45 a.m.-10:30 a.m.
Session Title: Arrhythmias: Devices II – Improving Outcomes in Patients with Implantable Devices: Tweaking the Well-Functioning Machine
Abstract Category: 8. Arrhythmias: Devices
Presentation Number: 1190-37
- 2013 American College of Cardiology Foundation